XTalks

JANUARY 26, 2024

Technological advancements are revolutionizing cancer research and therapies. This technology, which allows for precise editing of DNA at specific locations, has been a major focus in the field due to its potential to directly target and modify cancer-causing genes.

Research 118

Research Gene Editing Gene Genetics 118

Worldwide Clinical Trials

JULY 8, 2024

Genetic Factors : Certain genetic mutations, such as those in DNA repair genes, can affect how cells respond to radiation. Individuals with familial cancer syndrome may have inherited mutations that predispose them to cancer development, affecting genes involved in DNA repair and cell cycle regulation.

Hormones 130

Hormones Regulation Clinical Trials Clinical Trials 130

The Pharma Data

DECEMBER 23, 2020

” Dr. Stanley Plotkin , Professor Emeritus at The Wistar Institute, said, “INOVIO’s DNA vaccine appeared to be quite safe with few significant reactions but yet induced both antibody and T cell responses to SARS-CoV-2.” . PLYMOUTH MEETING, Pa. , PLYMOUTH MEETING, Pa. , mg and 2.0

DNA 40

DNA Vaccination Vaccine Immune Response 40

pharmaphorum

APRIL 7, 2021

The collaboration will focus on combining Artios’ DNA damage response (DDR) drug candidates with Novartis’ radioligand therapies, which consist of tumour-targeting molecules carrying radioactive isotopes that can deliver a cell-killing dose of radiation to malignant cells. It’s also providing research funding.

DNA 52

DNA Licensing Licensing Gene Therapy 52

XTalks

JANUARY 19, 2024

When alpha-emitting radionuclides are delivered to cancer cells, the emitted alpha particles cause substantial damage to the DNA of the cells, leading to cell death. Advantages of Alpha Emitter Therapy Over the past two decades, the radiological and chemical properties of alpha emitting isotopes have regained prominence in medical physics.

DNA 66

DNA Radiology FDA Approval Development 66

XTalks

NOVEMBER 7, 2022

Liquid biopsy tests in oncology involve isolating entities such as circulating tumor cells (CTC), circulating tumor DNA (ctDNA) and tumor-derived exosomes. The cfDNA that originates from tumors is called circulating tumor DNA (ctDNA). These tumor-derived entities are used to derive genomic and proteomic data.

Clinical Trials 98

Clinical Trials Clinical Trials Trials FDA Approval 98

Intouch Solutions

SEPTEMBER 27, 2024

From the increasing use of next generation sequencing based (NGS) tests in everyday clinical settings to groundbreaking research on tumor mutations that can help identify the most effective therapies, the promise of personalized cancer treatment is rapidly becoming a reality. And a lot of this biomarker research is fueled by AI.

DNA 59

DNA Trials Antibody Marketing 59